CoDa Therapeutics
Therapeutics for tissue repair targeting gap junction modulation
About CoDa Therapeutics
Originally founded as CoDa Therapeutics in 2005, the company rebranded to Ocunexus Therapeutics and operates as a clinical-stage biopharmaceutical firm. The company was established based on inventions from the laboratories of Professor Colin Green of the University of Auckland and Professor David Becker of University College London. Colin Green continues to serve as the Founder & Chief Scientific Officer. Ocunexus focuses on developing treatments for tissue repair and wound care by targeting the modulation of gap junctions, specifically the protein connexin43 (Cx43).
The company's lead product candidate is Nexagon®, a natural, unmodified antisense oligonucleotide designed to downregulate the expression of Cx43. This protein is often overexpressed in pathological conditions and injuries, leading to inflammation and hindering the healing process. By modulating Cx43, Nexagon® aims to reduce lesion spread, swelling, inflammation, and scarring, while improving wound closure rates across various tissue types, including the eye, skin, and nerves. The technology represents a novel approach by targeting the body's natural healing mechanisms.
Ocunexus' business model involves developing its proprietary compounds through clinical trials and entering into licensing agreements for commercialization. In a significant milestone, Ocunexus entered into a worldwide licensing agreement with Eyevance Pharmaceuticals (later acquired by Santen) for Nexagon® for the orphan indication of persistent corneal epithelial defect (PED). This collaboration progressed Nexagon® into later-stage clinical trials. The company's pipeline has also included Peptagon™, a peptide-based medicine for blocking gap junctions. Ocunexus targets unmet clinical needs in ophthalmology and other indications characterized by pathological connexin43 hemichannel overexpression.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2021 | $0 | — | Inflammx Therapeutics | — |
| DEBTDebt | Jun 2016 | $750K | — | Undisclosed | — |
Growth signals
Latest recorded traffic for CoDa Therapeutics is 0 monthly website visits. CoDa Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CoDa Therapeutics in the San Diego ecosystem
The CoDa Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
GBS Venture Partners
Series B and later1 investor entered at this stage
Square 1 Bank
Other known investors3 additional known investors
Inflammx Therapeutics
The University of Auckland
University College London
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about CoDa Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CoDa Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










